Kathryn Lemery-Chalfant

3/10/2022-2/28/2027  MPI’s Kathryn Lemery-Chalfant & Mary Davis, NICHD, “Genetic and environmental origins of the development of pain in children,” 2R01 HD086085, $3,534,642 total costs.

12/1/2020-11/30/2025 MPI’s Kathryn Lemery-Chalfant and Leah Doane, NICHD 2R01 HD079520-06, “Social and genetic contributions to children’s sleep, health and functioning.” $4,181,123 total costs.

4/15/2022-2/28/2026   MPI’s Kathryn Lemery-Chalfant & Jenn-Yun Tein, NIDA, “Parent-Child Interaction Dynamics Mediate Genetic and Prevention Effects on the Development of Adolescent Substance Use Disorders.”  R01 DA053740, $2,130,704 total costs. Percent recognition: 40%.

1/1/2023-11/30/2027  MPIs Erika Westling, Kathryn Lemery-Chalfant, Jazmin Brown-Iannuzzi, & Daniel Shaw, NIMH, “Preventing adult mental health problems from early childhood in the contexts of genetic susceptibility, poverty, racism, and the COVID-19 pandemic.” R01 MH131670, $3,801,453 total costs.

12/1/2023-11/30/2028  Co-Investigator, NIAAA, “Gene-environment interplay and alcohol use among racially-ethnically diverse youth,” (PI Jinni Su). R01 AA031281. Total costs $1,840,158.

7/1/2023-6/30/2026  MPIs Candace Lewis and Kathryn Lemery-Chalfant, IMHR, “Isolating environmentally induced DNA methylation patterns associated with psychopathology in adolescent twins.” $125,000 total costs.

7/1/2021-6/30/2023  Co-Investigator, NIDA, “Research training in drug abuse prevention: Closing the research-practice gap,” (PI Gonzales and Berkel). 2T32 DA039772-06, $2,294,493 total costs.

6/1/2021-5/31/2023  Sponsor, NIH F31 HD103374-01A1, “Novel measures of culture and relation to self-regulation,” (PI Gianna Rea-Sandin). $107,904 total costs.